ABL1

ENSG00000097007
Target class
Kinase
Chromosome
9
Approved drugs
11
Clinical candidates (approved and in development)
24

Approved drugs
11
Clinical candidates (approved and in development)
24

Chemical probe available
Yes

Target name
ABL1
Gene name
ABL proto-oncogene 1, non-receptor tyrosine kinase
Gene symbol
ABL1
Previous gene symbols
  • ABL
Protein name
Tyrosine-protein kinase ABL1 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 1) (Abelson tyrosine-protein kinase 1) (Proto-oncogene c-Abl) (p150)

  • JTK7
  • c-ABL
  • p150

Gene biotype
Protein coding
Gene family
SH2 domain containing|Abl family tyrosine kinases
Target class
Kinase
Target type
Human gene

Tissues expressed in
54
Protein localisation evidence grade
Supported
Highest tissue expression
166.08
Tissue specificity (Gini)
0.403
Tissue specificity (tau)
0.671

KEGG gene identifiers
  • hsa:25
Protein interaction confidence
0.850015
Protein interaction partners
132

  • R-HSA-2029482
  • R-HSA-428890
  • R-HSA-525793
  • R-HSA-5663213
  • R-HSA-5685938
  • R-HSA-5693565
  • R-HSA-69231
  • R-HSA-8939236
  • R-HSA-8940973
  • R-HSA-9664422
  • R-HSA-983231
  • R-HSA-9841922
  • R-HSA-9860927

End position
130887675
Start position
130713043
Chromosome
9
Strand
Forward

Ensembl gene ID
ENSG00000097007
HGNC ID
HGNC:76
www.genenames.org
NCBI Gene ID
25
UniProt ID
P00519

  • Cytoplasm, cytoskeleton. Nucleus. Mitochondrion . Note=Shuttles between the nucleus and cytoplasm depending on environmental signals. Sequestered into the cytoplasm through interaction with 14-3-3 proteins. Localizes to mitochondria in response to oxidative stress (By similarity). .
  • SUBCELLULAR LOCATION: [Isoform IB]: Nucleus membrane
  • Lipid-anchor. Note=The myristoylated c-ABL protein is reported to be nuclear.
  • Nuclear bodies
  • Nucleoplasm

Tissue specificity (tau)
0.671492
Expression inequality (Gini)
0.402965

Expression in transcripts per million

Colon - Sigmoid
166.08
Uterus
138.15
Cervix - Endocervix
135.02
Cervix - Ectocervix
127.5
Esophagus - Gastroesophageal Junction
126.28

Expression in transcripts per million

  • Colon - Sigmoid166.08
  • Uterus138.15
  • Cervix - Endocervix135.02
  • Cervix - Ectocervix127.5
  • Esophagus - Gastroesophageal Junction126.28
  • Fallopian Tube124.41
  • Bladder120.83
  • Esophagus - Muscularis119.66
  • Artery - Tibial113.06
  • Ovary105.05
  • Thyroid92.79
  • Cells - Cultured fibroblasts91.41
  • Artery - Aorta88.34
  • Adipose - Subcutaneous77.4
  • Colon - Transverse76.63
  • Artery - Coronary76.29
  • Nerve - Tibial74.09
  • Breast - Mammary Tissue73.25
  • Adipose - Visceral (Omentum)72.75
  • Vagina71.34
  • Prostate70.22
  • Lung59.17
  • Pituitary56.83
  • Small Intestine - Terminal Ileum53.95
  • Skin - Sun Exposed (Lower leg)51.28

And 29 more, listed on the interactive page.

And 16 more, listed on the interactive page.

And 1 more, listed on the interactive page.

  • heart disease

    Studies

    • preclinical: Important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: Maintains ER homeostasis. left ventricular dysfunction is seen in rodents treated with imatinib

    Biological samples

    • cardiovascular system
    PubMed 21283106
    pubmed.ncbi.nlm.nih.gov

  • regulation of catalytic activity

    Studies

    • biochemical: NVS_ENZ_hAbl, is one of one assay component(s) measured or calculated from the NVS_ENZ_hAbl assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.

    Biological samples

    • cell-free
    Evidence source
    www.epa.gov

Related records

Trials (1,641)

Drugs (28)